TrypLEᵀᴹ ELISA Kit

Sample

Biological samples

Detection Method

sELISA

Intended Use

The ELISA Kit is a highly sensitive, universal detection kit capable of accurately identifying a variety of recombinant, non-animal-derived trypsin and its analogs. The detection range of this kit is 0.1–16 ng/mL, with the limit of quantitation is 0.1 ng/mL.

Contents of Kit

1. Microplate: 96 well polystyrene microplate (12 strips of 8 wells).
2. Standard (1 μg/mL): 1×300 μL.
3. Enzyme-labeled Antibody: 1×15 mL, antibody conjugated to horseradish peroxidase (HRP) with preservatives.
4. Sample Dilution: 30 mL.
5. Wash Buffer 20×: 30 mL.
6. Chromogen Solution A: 8 mL, avoid direct light.
7. Chromogen Solution B: 8 mL, avoid direct light.
8. Stop Solution: 15 mL.
9. 3 Sealing Film.

Storage

The kit should be stored at 2–8°C, protected from light. Under these conditions, the kit is stable for 12 months. Once opened, any unused components must continue to be stored at 2–8°C, protected from light. The production date and expiration date are indicated on the kit label.

Precision

Accuracy (measurement deviation): ≤15%
Repeatability (within-batch difference): ≤10%

Detection Range

0.1-16ng/mL

Detection Limit

LOD: ＜0.1ng/mL
LOQ: 0.1ng/mL

General Description

Recombinant trypsin analogs are bioengineered, non-animal-derived enzymes. In cell culture applications, they serve as an effective substitute for porcine- or bovine-derived trypsin for the dissociation of adherent cells. Due to the absence of animal- or human-derived components in their manufacturing process, these analogs typically exhibit high purity and enhanced specificity compared to natural trypsin formulations. Moreover, they are characterized by a gentler action on cells; the digestion process can be terminated simply by dilution with a buffer, eliminating the need for trypsin inhibitors. This significantly reduces potential interference with cultured cells. Consequently, recombinant trypsin analogs represent a highly promising alternative to traditional trypsin.
Cell culture currently plays an essential role in the biopharmaceutical manufacturing process, with trypsin serving as an indispensable enzyme for routine cell passaging. The introduction of recombinant trypsin analogs as exogenous substances into biopharmaceutical production workflows, however, presents potential safety concerns. Consequently, it is necessary to detect and quantify residual recombinant trypsin analogs in the final product to ensure process safety and product quality.

Standard Curve